Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Rating of “Moderate Buy” from Brokerages

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has earned a consensus rating of “Moderate Buy” from the eight research firms that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $56.00.

Several brokerages recently commented on AGIO. HC Wainwright reaffirmed a “buy” rating and issued a $56.00 price target on shares of Agios Pharmaceuticals in a research note on Thursday, September 4th. Bank of America cut their price objective on Agios Pharmaceuticals from $52.00 to $51.00 and set a “buy” rating for the company in a report on Tuesday, July 22nd. Finally, Scotiabank lowered their target price on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating on the stock in a report on Monday, July 28th.

Agios Pharmaceuticals Stock Up 1.2%

NASDAQ:AGIO opened at $36.72 on Friday. Agios Pharmaceuticals has a 12-month low of $23.42 and a 12-month high of $62.58. The firm has a market capitalization of $2.13 billion, a PE ratio of 3.34 and a beta of 0.87. The firm has a 50-day moving average price of $37.74 and a 200 day moving average price of $33.27.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.19). Agios Pharmaceuticals had a net margin of 1,590.42% and a negative return on equity of 3.49%. The company had revenue of $12.50 million for the quarter, compared to analyst estimates of $9.46 million. On average, research analysts expect that Agios Pharmaceuticals will post -6.85 EPS for the current year.

Insider Activity

In other news, CEO Brian Goff sold 11,085 shares of the firm’s stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $36.67, for a total transaction of $406,486.95. Following the completion of the sale, the chief executive officer owned 123,528 shares of the company’s stock, valued at approximately $4,529,771.76. This trade represents a 8.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Tsveta Milanova sold 2,770 shares of the business’s stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total value of $92,905.80. Following the completion of the transaction, the insider directly owned 26,122 shares in the company, valued at $876,131.88. The trade was a 9.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 65,994 shares of company stock valued at $2,341,232. Corporate insiders own 4.93% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in AGIO. GF Fund Management CO. LTD. bought a new position in shares of Agios Pharmaceuticals in the fourth quarter worth about $39,000. NewEdge Advisors LLC acquired a new stake in shares of Agios Pharmaceuticals in the first quarter valued at approximately $40,000. CWM LLC raised its position in Agios Pharmaceuticals by 150.2% in the 1st quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 996 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Agios Pharmaceuticals by 16.7% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 320 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its position in Agios Pharmaceuticals by 16.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 499 shares during the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.